当前位置: 首页 >> 检索结果
5221. Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial.
作者: Doortje I Krijbolder.;Marloes Verstappen.;Bastiaan T van Dijk.;Yousra J Dakkak.;Leonie E Burgers.;Aleid C Boer.;Yune Jung Park.;Marianne E de Witt-Luth.;Karen Visser.;Marc R Kok.;Esmeralda T H Molenaar.;Pascal H P de Jong.;Stefan Böhringer.;Tom W J Huizinga.;Cornelia F Allaart.;Ellis Niemantsverdriet.;Annette H M van der Helm-van Mil.
来源: Lancet. 2022年400卷10348期283-294页
Rheumatoid arthritis is the most common autoimmune disease worldwide and requires long-term treatment to suppress inflammation. Currently, treatment is started when arthritis is clinically apparent. We aimed to evaluate whether earlier intervention, in the preceding phase of arthralgia and subclinical joint inflammation, could prevent the development of clinical arthritis or reduce the disease burden.
5222. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
作者: Kristian Reich.;Jacob P Thyssen.;Andrew Blauvelt.;Kilian Eyerich.;Weily Soong.;Zakiya P Rice.;H Chih-Ho Hong.;Norito Katoh.;Fernando Valenzuela.;Marco DiBonaventura.;Tamara A Bratt.;Fan Zhang.;Claire Clibborn.;Ricardo Rojo.;Hernan Valdez.;Urs Kerkmann.
来源: Lancet. 2022年400卷10348期273-282页
Phase 3 trials have assessed efficacy of abrocitinib versus placebo in moderate-to-severe atopic dermatitis, a common immunoinflammatory skin disease. This study assessed the efficacy and safety of abrocitinib versus dupilumab.
5239. From food price crisis to an equitable food system.
作者: Corinna Hawkes.;Ramya Ambikapathi.;Kim Anastasiou.;Jessica Brock.;Luciana Castronuovo.;Naomi Fallon.;Hazel Malapit.;Assumpta Ndumi.;Folake Samuel.;Maryse Umugwaneza.;Milkah N Wanjohi.;Christina Zorbas.
来源: Lancet. 2022年400卷10350期413-416页 |